Fascaplysin (114719-57-2) is a novel marine natural product isolated from?Thorectandra sp.1?A potent and selective inhibitor of cyclin dependent kinase 4/cyclin D1 (IC50?= 0.35 μM) and is less selective for Cdk6/D1 (IC50?= 3.4 μM). Displays antiangiogenic acitivity.2?Fascaplysin displays high cytotoxic activity against small cell lung cancer cell lines acting via multiple mechanisms including topoisomerase I, DNA integrity and ROS.3
1) Soni?et al. (2000),?Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product; Biochem. Biophys. Res. Commun.,?275?877
2) Lin?et al. (2007),?Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo; Cancer Chemother. Pharmacol.,?59?439
3) Hamilton?et al. (2014),?Cytotoxic effects of fascaplysin against small cell lung cancer cell lines; Mar. Drugs,?12?1377
